HLA-A and B-cell non-Hodgkin lymphoma: These responses effectively inhibited EBV replication and protected against EBV-induced B cell lymphomas in the humanized mouse model engrafted with PBMCs from an HLA-A*02:01(+), HLA-A*02:03(+), and HLA-A*02:07(+) individuals.